+ Filter
Loading...
Custom Services order now ship next day

Anti-CD28 Recombinant Antibody Products

Anti-CD28 Recombinant Antibody Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs is fully dedicated to accelerating the research and discovery of the target CD28 through the provision of premium, advanced recombinant antibodies specifically engineered for this purpose. Developed with innovative technology, our products deliver exceptional reliability and performance, meeting the needs of researchers worldwide. By supplying these top-tier antibodies, we strive to empower impactful scientific breakthroughs and drive progress in the field of biomedical research, particularly in studies focusing on the critical role of CD28.

CD28: A crucial molecule in the immune disorders

CD28 is an essential surface molecule predominantly found on T cells, functioning as a key co-stimulatory receptor. It plays a significant role in promoting T cell activation, proliferation, and survival by interacting with ligands on antigen-presenting cells to deliver critical signals. This interaction is fundamental to regulating immune responses. Research into CD28 is immensely valuable, offering insights into the intricate mechanisms of immune regulation and the maintenance of immune balance. Understanding CD28's role provides a deeper perspective on the development of immune disorders, such as autoimmune diseases and immunodeficiencies. Furthermore, CD28 is a promising target in immunotherapy, as modulating its pathways could pave the way for innovative treatments for cancer and other immune-related conditions.

Alternative Names

CD28 molecule; Tp44; IMD123

Background

Enables protein kinase binding activity. Acts upstream of or within several processes, including positive regulation of immune response; positive regulation of intracellular signal transduction; and regulation of lymphocyte activation. Located on the external side of the plasma membrane and immunological synapse. Human ortholog(s) of this gene are implicated in multiple sclerosis and type 1 diabetes mellitus. Orthologous to human CD28 (CD28 molecule).

Anti-CD28 rAb Products

We are dedicated to accelerating research and discovery by providing high-quality anti-CD28 recombinant antibody products at an outstanding value, complemented by excellent technical support.

Cat. No. Product Name Target Species Host Species Applications
TAB-064LC Anti-Human CD28 Recombinant Antibody (TGN1412) Human Human ELISA; Stim
TAB-H46 Humanized Anti-CD28 Recombinant Antibody (clone Lulizumab) Human Human IP; IF; FuncS; FC; Neut; ELISA; IHC
PABX-031 Recombinant Mouse Anti-CD28 Antibody (5.11A1) Human Mouse WB; ELISA; FuncS; Activ
TAB-065LC Human Anti-CD28 Recombinant Antibody Human Human ELISA
HPAB-0132CQ Human Anti-CD28 Recombinant Antibody (clone FR255734) Human Human ELISA; IHC; Block; FuncS

Creative Quality Control

We have established a robust quality management system to ensure the excellence of our products and help our customers streamline drug development by meeting and exceeding their expectations.

Fig.1 SDS-PAGE analysis of TAB-064LC. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).

Fig.2 SEC-HPLC analysis of TAB-064LC. (Creative Biolabs Original)Fig.2 SEC-HPLC analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).

Fig.3 ELISA analysis of TAB-064LC. (Creative Biolabs Original)Fig.3 ELISA analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).

Fig.4 WB analysis of TAB-064LC. (Creative Biolabs Original)Fig.4 WB analysis of anti-CD28 antibody
(Cat# TAB-064LC, Creative Biolabs).

Customer Reviews

Excellent
Lu**a
Anti-Human CD28 Recombinant Antibody (TGN1412) (Cat#: TAB-064LC)
I utilized the Anti-Human CD28 Recombinant Antibody in my research on immune response modulation, and it demonstrated exceptional efficacy in exploring the role of CD28 in T cell activation. The antibody yielded reliable and consistent results, enabling precise data analysis and contributing significantly to the progress of my study. It offered valuable insights into the immune system's mechanisms involving CD28, greatly enhancing my understanding and advancing my research objectives.
13/Mar/2022
Excellent
Ja**e
Humanized Anti-CD28 Recombinant Antibody (clone Lulizumab) (Cat#: TAB-H46)
In my research on the mechanisms underlying autoimmune diseases, I employed the humanized Anti-CD28 Recombinant Antibody. Using flow cytometry, I evaluated its binding to cells expressing CD28. The antibody delivered remarkable performance, demonstrating high specificity and strong affinity. This resulted in accurate and consistent data, significantly supporting the objectives of my study.
3/Apr/2023
Excellent
S**th
Recombinant Mouse Anti-CD28 Antibody (5.11A1) (Cat#: PABX-031)
We purchased this mouse anti-CD28 recombinant antibody to evaluate its interaction with human CD28 in ELISA experiments. When used at the recommended concentration, it delivered excellent positive results. The antibody exhibited remarkable specificity, accurately binding to CD28 with no off-target effects. Furthermore, its impressive stability ensures dependable storage and consistent performance during applications.
25/Oct/2023

rAb Production

Our services encompass the entire process, from gene synthesis to the production of high-quality recombinant antibodies, ensuring a seamless experience for our customers. With this foundation, we are well-equipped to deliver outstanding antibody production solutions tailored to the needs of research specialists.

Featured Anti-CD28 Recombinant Antibody Production PlatformsFig.5 Milligram-scale anti-CD28 recombinant antibody production. (Creative Biolabs Original)
Fig.5 Milligram-scale recombinant antibody production.

Fig.6 Gram-scale anti-CD28 recombinant antibody production. (Creative Biolabs Original)Fig.6 Gram-scale recombinant antibody production

rAb Modalities

Creative Biolabs is dedicated to offering researchers an extensive selection of advanced, high-quality recombinant antibodies in various formats. These formats encompass full-length antibodies, scFv, Fab, scFab, Fc fusion proteins, and more, ensuring diverse options to meet specific research needs.

Fig.7 Full Length Anti-CD28 Recombinant Antibody Production and Modalities. (Creative Biolabs Original)Fig.7 Full Length Anti-CD28 Recombinant Antibody Production and Modalities

Drug Information Targeting CD28

Table 1. Therapeutic approaches targeting CD28 in clinical development.

Research phase Company Classification Indications Details
Launched - 2021 Bristol-Myers Squibb
Celgene
Biologics Acute lymphocytic leukemia;
B-cell chronic lymphocytic leukemia
It is an autologous anti-CD19 CAR T-cell immunotherapy developed by Bristol-Myers Squibb (formerly Celgene).
Launched - 2020 Kite Pharma Biologics B-cell acute lymphocytic leukemia;
Chronic lymphocytic leukemia
This is an autologous anti-CD19 CAR T-cell therapy developed by Kite Pharma (a Gilead company), first launched in the U.S.
Launched - 2017 Adimab
Daiichi Sankyo
Biologics Acute lymphocytic leukemia;
B-cell acute lymphocytic leukemia
It consists of autologous peripheral blood lymphocytes transduced with a chimeric antigen receptor (CAR) against CD19 developed by Kite Pharma (a Gilead company).
Pre-Registered Atox Bio Peptides Acute kidney injury;
Avian influenza;
Immunological Disorders
It is an immunomodulator peptide targeting the CD28 co-stimulatory receptor, currently under regulatory review in the U.S. for the treatment of suspected organ dysfunction or failure.
Phase II AbbVie
Alpine Immune Sciences
Biologics Arthritis;
Autoimmune disease
It is a first-in-class dual ICOS/CD28 antagonist in phase II clinical development at AIS Operating (formerly, Alpine Immune Sciences) for the treatment of adults with moderate to severe active systemic lupus erythematosus (SLE).
Phase II Bristol-Myers Squibb Biologics Systemic lupus erythematosus It is a human domain antibody targeting human CD28. The product had been evaluated in phase II clinical trials at Bristol-Myers Squibb for the treatment of systemic lupus erythematosus; however, no recent development has been reported.
Phase II TeGenero
TheraMAB
Biologics Autoimmune disease It is a humanized superagonistic anti-CD28 monoclonal antibody that completed phase II development at TheraMAB for the treatment of adult patients with active systemic lupus erythematosus not adequately controlled with current concomitant treatment.
Phase I/II Regeneron Biologics Cancer This is a bispecific monoclonal antibody targeting CD28 and epidermal growth factor receptor, is in early clinical development at Regeneron for the treatment of adult patients with advanced solid tumors that are naïve to anti-PD-1/PD-L1 therapies in combination with cemiplimab.
Phase I/II Regeneron Biologics Cancer It is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) and CD28 in phase I/II clinical development at Regeneron for the treatment of patients with metastatic, castration-resistant prostate cancer (mCRPC) in combination with cemiplimab.
Phase I/II Memorial Sloan-Kettering Cancer Center Biologics Cancer It is a cell therapy consisting of T cells targeting human mesothelin (MSLN), is undergoing early clinical evaluation at the Memorial Sloan-Kettering Cancer Center for the treatment of patients with malignant pleural disease.
Phase I Alpine Immune Sciences Biologics Cancer It is a PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 T cell costimulatory, is in early clinical development at AIS Operating (formerly, Alpine Immune Sciences) for the treatment of patients with advanced solid tumors or lymphomas.

For more details about our anti-CD28 recombinant antibody products, please don’t hesitate to Contact us. Our team is eager to provide you with the information you need and looks forward to establishing a mutually beneficial partnership that will enhance your research efforts and drive scientific progress.

  • 0
  • 0
Cart
    Go to compare

    Go to compare